Ensysce Biosciences Inc Financials

ENSC

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Ensysce Biosciences Inc (ENSC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 66/100

Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Ensysce Biosciences Inc has an operating margin of -129.2%, meaning the company retains $-129 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -480.5% the prior year.

Growth

100

Ensysce Biosciences Inc's revenue surged 133.6% year-over-year to $5.2M, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

Ensysce Biosciences Inc carries a low D/E ratio of 0.60, meaning only $0.60 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 89/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 2.42, Ensysce Biosciences Inc holds $2.42 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 77/100.

Piotroski F-Score Neutral

4/9

Ensysce Biosciences Inc passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

0.94x

For every $1 of reported earnings, Ensysce Biosciences Inc generates $0.94 in operating cash flow (-$7.5M OCF vs -$8.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-760.6x

Ensysce Biosciences Inc earns $-760.6 in operating income for every $1 of interest expense (-$6.7M vs $9K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Revenue

$5.2M

YoY+133.6%

Ensysce Biosciences Inc generated $5.2M in revenue in fiscal year 2024. This represents an increase of 133.6% from the prior year.

EBITDA

-$6.7M

YoY+37.2%

Ensysce Biosciences Inc's EBITDA was -$6.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 37.2% from the prior year.

Free Cash Flow

N/A

Net Income

-$8.0M

YoY+24.8%

Ensysce Biosciences Inc reported -$8.0M in net income in fiscal year 2024. This represents an increase of 24.8% from the prior year.

EPS (Diluted)

$-11.45

Ensysce Biosciences Inc earned $-11.45 per diluted share (EPS) in fiscal year 2024. This represents an increase of 83.7% from the prior year.

Cash & Debt

$3.5M

YoY+211.7%

5Y CAGR+27.0%

Ensysce Biosciences Inc held $3.5M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

Ensysce Biosciences Inc had 1M shares outstanding in fiscal year 2024. This represents an increase of 546.4% from the prior year.

Gross Margin

N/A

Operating Margin

-129.2%

YoY+351.3pp

Ensysce Biosciences Inc's operating margin was -129.2% in fiscal year 2024, reflecting core business profitability. This is up 351.3 percentage points from the prior year.

Net Margin

-153.3%

YoY+323.1pp

Ensysce Biosciences Inc's net profit margin was -153.3% in fiscal year 2024, showing the share of revenue converted to profit. This is up 323.1 percentage points from the prior year.

Return on Equity

N/A

R&D Spending

$7.2M

YoY-4.9%

Ensysce Biosciences Inc invested $7.2M in research and development in fiscal year 2024. This represents a decrease of 4.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

ENSC Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$5.2M+133.6%	$2.2M-11.6%	$2.5M-28.5%	$3.5M-10.2%	$3.9M	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$7.2M-4.9%	$7.6M-61.7%	$19.8M+322.9%	$4.7M+6.8%	$4.4M	N/A
SG&A Expenses	$4.7M-11.9%	$5.4M-22.4%	$6.9M-63.1%	$18.7M+1520.2%	$1.2M	N/A
Operating Income	-$6.7M+37.2%	-$10.7M+55.8%	-$24.2M-21.9%	-$19.9M-1131.7%	-$1.6M+51.5%	-$3.3M
Interest Expense	$9K-97.5%	$354K+223.2%	$110K-91.5%	$1.3M+30.1%	$995K	N/A
Income Tax	N/A	N/A	N/A	N/A	$244K-56.0%	$555K
Net Income	-$8.0M+24.8%	-$10.6M+56.1%	-$24.2M+16.9%	-$29.1M-776.1%	$4.3M+503.9%	-$1.1M
EPS (Diluted)	$-11.45	$-70.40+49.5%	$-139.42-9320.3%	$-1.48	$0.00	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'23	Q3'24	Q2'24	Q1'24	Q4'22
Revenue	$493K-64.0%	$1.4M+3.9%	$1.3M+156.2%	$515K+18.3%	$435K-11.2%	$490K-37.9%	$790K-44.9%	$1.4M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$3.0M+53.6%	$1.9M+2.0%	$1.9M-15.6%	$2.2M+16.6%	$1.9M+16.5%	$1.6M-8.5%	$1.8M-72.9%	$6.6M
SG&A Expenses	$1.3M+6.7%	$1.2M-14.5%	$1.4M-2.5%	$1.4M+17.1%	$1.2M+7.6%	$1.1M-26.6%	$1.6M+54.6%	$1.0M
Operating Income	-$3.7M-113.7%	-$1.8M+11.0%	-$2.0M+37.7%	-$3.2M-16.6%	-$2.7M-18.0%	-$2.3M+10.4%	-$2.6M+58.7%	-$6.2M
Interest Expense	$3K	$0-100.0%	$909-99.7%	$345K+4407.8%	$8K	$0-100.0%	$1K-97.1%	$52K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$3.7M-115.1%	-$1.7M+10.9%	-$1.9M+44.5%	-$3.5M-30.2%	-$2.7M-20.2%	-$2.2M-2.2%	-$2.2M+60.0%	-$5.5M
EPS (Diluted)	$-1.29-63.3%	$-0.79+43.2%	$-1.39	$-66.47	$-0.87+11.2%	$-0.98	$-2.08	N/A

ENSC Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$5.6M+106.7%	$2.7M-54.0%	$5.9M-64.2%	$16.4M+4566.6%	$352K-99.8%	$196.5M
Current Assets	$5.3M+133.5%	$2.3M-56.8%	$5.3M-66.2%	$15.7M+4402.3%	$348K-71.0%	$1.2M
Cash & Equivalents	$3.5M+211.7%	$1.1M-64.3%	$3.1M-74.3%	$12.3M+6215.1%	$194K-81.7%	$1.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.2M-34.0%	$3.4M-66.1%	$9.9M-59.7%	$24.6M+261.8%	$6.8M-96.5%	$191.5M
Current Liabilities	$2.2M-33.8%	$3.3M-64.8%	$9.5M-42.6%	$16.5M+135.1%	$7.0M+153.0%	$2.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$3.7M+1248.6%	-$323K+91.3%	-$3.7M+52.9%	-$7.9M-22.3%	-$6.4M-228.8%	$5.0M
Retained Earnings	-$129.5M-6.6%	-$121.6M-9.6%	-$110.9M-29.2%	-$85.8M-53.4%	-$56.0M-40833.6%	-$137K

Metric	Q3'25	Q2'25	Q1'25	Q4'23	Q3'24	Q2'24	Q1'24	Q4'22
Total Assets	$3.2M-43.0%	$5.6M+20.9%	$4.6M+70.3%	$2.7M-15.9%	$3.2M-49.4%	$6.4M+62.4%	$3.9M-33.5%	$5.9M
Current Assets	$2.9M-44.6%	$5.3M+20.0%	$4.4M+92.3%	$2.3M-17.0%	$2.8M-52.9%	$5.9M+73.7%	$3.4M-36.4%	$5.3M
Cash & Equivalents	$1.7M-24.3%	$2.2M-27.5%	$3.1M+171.7%	$1.1M-23.3%	$1.5M-61.8%	$3.8M+170.5%	$1.4M-55.0%	$3.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$2.3M-8.3%	$2.5M+32.9%	$1.9M-43.7%	$3.4M+63.0%	$2.1M-19.6%	$2.6M-36.9%	$4.1M-59.0%	$9.9M
Current Liabilities	$2.3M-8.3%	$2.5M+42.7%	$1.8M-47.2%	$3.3M+64.1%	$2.0M-19.3%	$2.5M-36.7%	$4.0M-58.0%	$9.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$1.2M-64.5%	$3.4M+11.2%	$3.0M+1044.4%	-$323K-121.7%	$1.5M-63.9%	$4.1M+2370.5%	$167K+104.5%	-$3.7M
Retained Earnings	-$137.0M-2.8%	-$133.2M-1.3%	-$131.5M-8.2%	-$121.6M-3.0%	-$118.1M-2.3%	-$115.4M-2.0%	-$113.1M-2.0%	-$110.9M

ENSC Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$7.5M+30.4%	-$10.8M+39.7%	-$17.9M-117.0%	-$8.2M-560.8%	-$1.2M+12.5%	-$1.4M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	$5K	N/A	$183.4M+1447.3%	$11.9M
Financing Cash Flow	$9.9M+12.9%	$8.8M-0.1%	$8.8M-56.8%	$20.3M+1746.6%	$1.1M+110.0%	-$11.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	$184.8M+1495.2%	$11.6M

Metric	Q3'25	Q2'25	Q1'25	Q4'23	Q3'24	Q2'24	Q1'24	Q4'22
Operating Cash Flow	-$1.9M+31.1%	-$2.7M-58.5%	-$1.7M+5.2%	-$1.8M+20.4%	-$2.3M+27.2%	-$3.1M+13.8%	-$3.6M-9.4%	-$3.3M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
Financing Cash Flow	$1.5M-22.2%	$1.9M+48.3%	$1.3M-13.9%	$1.5M+1526.1%	-$102K-101.9%	$5.5M+194.5%	$1.9M-3.4%	$1.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ENSC Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-129.2%+351.3pp	-480.5%+479.4pp	-959.9%-397.2pp	-562.7%-521.7pp	-41.0%	N/A
Net Margin	-153.3%+323.1pp	-476.4%+482.9pp	-959.3%-133.9pp	-825.4%-935.0pp	109.7%	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-142.7%+249.7pp	-392.4%+19.0pp	-411.3%-233.8pp	-177.5%-1402.8pp	1225.3%+1225.9pp	-0.5%
Current Ratio	2.42+1.7	0.69+0.1	0.56-0.4	0.95+0.9	0.05-0.4	0.43
Debt-to-Equity	0.60+11.0	-10.40-7.7	-2.67+0.5	-3.12-2.1	-1.05-39.4	38.30
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'23	Q3'24	Q2'24	Q1'24	Q4'22
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-758.7%-631.0pp	-127.6%+21.4pp	-149.1%+463.6pp	-612.7%+9.1pp	-621.8%-154.1pp	-467.7%-143.3pp	-324.4%+108.2pp	-432.6%
Net Margin	-756.3%-629.9pp	-126.4%+21.0pp	-147.4%+533.0pp	-680.4%-62.4pp	-618.0%-161.5pp	-456.6%-179.0pp	-277.6%+104.6pp	-382.2%
Return on Equity	9.6%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-117.3%-86.2pp	-31.1%+11.1pp	-42.2%+87.2pp	-129.4%-45.8pp	-83.6%-48.4pp	-35.2%+20.8pp	-56.0%+37.1pp	-93.1%
Current Ratio	1.27-0.8	2.10-0.4	2.50+1.8	0.69-0.7	1.36-1.0	2.33+1.5	0.85+0.3	0.56
Debt-to-Equity	1.92+1.2	0.74+0.1	0.62+11.0	-10.40-11.8	1.39+0.8	0.62-23.8	24.40+27.1	-2.67
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Artelo Biosciences Inc ARTL

$3.3M

Silo Pharma Inc SILO

$3.9M

Polyrizon Ltd PLRZ

$14.2M

Titan Pharmaceut TTNP

$6.1M

Nucana NCNA

$8.9M

Frequently Asked Questions

What is Ensysce Biosciences Inc's annual revenue?

Ensysce Biosciences Inc (ENSC) reported $5.2M in total revenue for fiscal year 2024. This represents a 133.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Ensysce Biosciences Inc's revenue growing?

Ensysce Biosciences Inc (ENSC) revenue grew by 133.6% year-over-year, from $2.2M to $5.2M in fiscal year 2024.

Is Ensysce Biosciences Inc profitable?

No, Ensysce Biosciences Inc (ENSC) reported a net income of -$8.0M in fiscal year 2024, with a net profit margin of -153.3%.

What is Ensysce Biosciences Inc's earnings per share (EPS)?

Ensysce Biosciences Inc (ENSC) reported diluted earnings per share of $-11.45 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Ensysce Biosciences Inc's EBITDA?

Ensysce Biosciences Inc (ENSC) had EBITDA of -$6.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Ensysce Biosciences Inc's operating margin?

Ensysce Biosciences Inc (ENSC) had an operating margin of -129.2% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Ensysce Biosciences Inc's net profit margin?

Ensysce Biosciences Inc (ENSC) had a net profit margin of -153.3% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Ensysce Biosciences Inc's operating cash flow?

Ensysce Biosciences Inc (ENSC) generated -$7.5M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Ensysce Biosciences Inc's total assets?

Ensysce Biosciences Inc (ENSC) had $5.6M in total assets as of fiscal year 2024, including both current and long-term assets.

How much does Ensysce Biosciences Inc spend on research and development?

Ensysce Biosciences Inc (ENSC) invested $7.2M in research and development during fiscal year 2024.

How many shares does Ensysce Biosciences Inc have outstanding?

Ensysce Biosciences Inc (ENSC) had 1M shares outstanding as of fiscal year 2024.

What is Ensysce Biosciences Inc's current ratio?

Ensysce Biosciences Inc (ENSC) had a current ratio of 2.42 as of fiscal year 2024, which is generally considered healthy.

What is Ensysce Biosciences Inc's debt-to-equity ratio?

Ensysce Biosciences Inc (ENSC) had a debt-to-equity ratio of 0.60 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Ensysce Biosciences Inc's return on assets (ROA)?

Ensysce Biosciences Inc (ENSC) had a return on assets of -142.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Ensysce Biosciences Inc's cash runway?

Based on fiscal year 2024 data, Ensysce Biosciences Inc (ENSC) had $3.5M in cash against an annual operating cash burn of $7.5M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Ensysce Biosciences Inc's Piotroski F-Score?

Ensysce Biosciences Inc (ENSC) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Ensysce Biosciences Inc's earnings high quality?

Ensysce Biosciences Inc (ENSC) has an earnings quality ratio of 0.94x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Ensysce Biosciences Inc cover its interest payments?

Ensysce Biosciences Inc (ENSC) has an interest coverage ratio of -760.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Ensysce Biosciences Inc?

Ensysce Biosciences Inc (ENSC) scores 66 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.